Funding for this research was provided by:
Deparment of Health, UK (015/0306)
Text and Data Mining valid from 2019-05-02
Received: 14 November 2018
Accepted: 20 March 2019
First Online: 2 May 2019
Ethics approval and consent to participate
: This secondary data analysis was reviewed and approved as part of the HALT: Hepatitis trial by the National Research Ethics Service (NRES) Committee London, Brent (ref: 13/LO/0077). It was registered as ISRCTN24707359. All participants gave written informed consent to be part of the study.
: Not applicable.
: HRS reports funding from the Department of Health during the course of the study. JS, JM and MF report funding from the Department of Health and NIHR Clinical Research Network, UK, during the conduct of the study. GF reports personal fees from AbbVie, Gilead and Merck during the conduct of the study. All other authors report that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.